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Background: Severe renal manifestation of systemic lupus erythematosus (SLE) is not uncommon and is associated
with an indeterminate prognosis. Complete remission can be obtained, however, at least in the young when
chronic lesions are absent and adequate anti-inflammatory therapy is immediately initiated.
Case presentation: We report the unusual case of a 12-year-old girl who presented with severe oliguric renal
failure, macrohematuria and skin rash. Renal biopsy revealed the diagnosis of severe diffuse proliferative
glomerulonephritis (GN) with cellular crescents in 15 out of 18 glomeruli and full-house pattern in
immunofluorescence indicating lupus nephritis IVB according to WHO, IV-G(A) according to ISN/RPS classification.
The serological parameters confirmed the diagnosis of SLE and the patient was immediately treated with
methylprednisolone, cyclophosphamide and immunoadsorption. Initially, despite rapid amelioration of her general
condition, no substantial improvement of renal function could be achieved and the patient needed hemodialysis
treatment for 12 weeks. Unexpectedly, in the further follow-up at first diuresis increased and thereafter also
creatinine levels substantially declined so that hemodialysis could be discontinued. Today, 6 years after the initial
presentation, the patient has normal renal function and a SLEDAI score of 0 under a continuous
immunosuppressive therapy with Mycophenolate mofetil (MMF) and low dose steroid.
Conclusion: Despite the severity of the initial renal injury and the unfavourable renal prognosis the kidney
apparently has a tremendous capacity to recover in young patients when the damage is acute and adequate anti-
inflammatory therapy is initiated without delay.
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RemissionBackground
Lupus nephritis is a serious complication of systemic
lupus erythematosus (SLE). Especially in active diffuse
proliferative lupus nephritis (WHO class IV, ISN/RPS IV
A) a poor outcome with a high risk of end stage renal
disease has been reported [1]. A significant correlation
between proteinuria, GFR and severity of nephritis has
been observed. Proliferative lupus nephritis features the
most severe proteinuria and the lowest GFR-values [2].
Despite early and thoroughly elaborated aggressive im-
munosuppressive therapy many of these patients are* Correspondence: kerstin.benz@uk-erlangen.de
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reproduction in any medium, provided the orfaced with end stage renal disease and continuous
dialysis.
We report the case of a 12-year-old girl with severe
diffuse proliferative lupus nephritis type IV with cellular
crescents in 80% of glomeruli and oligoanuria at presen-
tation requiring dialysis treatment for several months.
However, due to intensive immunosuppressive treatment
complete recovery of renal function could finally be
achieved.
Case report
A 12-year-old Caucasian girl presented at her general
practitioner because of swollen legs and spotted skin
macular rash over her face, on her arms and on her
chest. She was also complaining about headaches, ab-
dominal pain, arthralgia and macroscopic haematuria. In
the last few weeks she had gained 4 kg body weight. Atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and






Figure 1 Renal biopsy. A, B, C: Active diffuse proliferative lupus
glomerulonephritis with cellular crescents (*) in 15 of 18 glomeruli,
marked inflammation of the interstitium and signs of acute tubular
necrosis (+). Please note that there is no chronic damage in the
kidney. In Figure 1C also markedly thickened, stiff appearing
glomerular basement membranes due to intramembranous and
subepithelial immune deposits (arrow) are seen. Light microscopy,
PAS Stain. Magnifications x 10 (A), x 20(B), x 40(C).
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poor general state with hypertension of 143/99 mmHg,
considerable oedema of the legs and facial rash. Labora-
tory results showed anemia (hemoglobin 9.2 g/dl),
leukopenia (2.650/μl), normal thrombocyte counts, acute
renal failure (creatinine 5.8 mg/dl, urea 166 mg/dl) with
hyperkalemia (6.4 mmol/l) and metabolic acidosis. Fur-
thermore, macroscopic haematuria with dysmorphic ery-
throcytes, proteinuria of 6.6 g/m2 body surface area per
day, serum albumin of 19.6 g/l and oliguria were
observed. Abdominal ultrasound demonstrated ascites
but no pleural or pericardial effusion, enlarged kidneys
with increased echogenicity and lacking corticomedul-
lary differentiation.
Further diagnostic tests showed extremely low com-
plement levels (C3 and C4 below detection level), mark-
edly elevated anti-nuclear-antibodies (ANA 1:320;
normal value <1:100) and a particularily strong increase
of anti-double-stranded nuclear antibodies (anti-dsDNA,
1500 U/ml; normal value <7 U/ml). Other autoimmune
phenomena were carefully excluded: tests for ANCA,
anti-GBM, anti-phospholipid antibodies, and anti-
extractable nuclear antigen all yielded negative results.
Neither the patient nor her relatives had any other im-
mune abnormality at present or in the past history. The
patient did not show any signs of hemolysis or abnormal
coagulation.
Renal biopsy performed immediately in the next
morning confirmed the diagnosis of renal involvement
in lupus erythematosus showing diffuse proliferative
glomerulonephritis (GN) with cellular crescents in 15 of
18 glomeruli, severe interstitial oedema, acute inflamma-
tion and acute tubular necrosis (Figure 1a-c). On im-
munofluorescence, IgA, IgG, IgM as well as C1q and
C3c depositions, i.e. a so-called fullhouse pattern, were
detected in a mesangiocapillary pattern (Figure 2). This
pattern of immune complex deposition was also con-
firmed on electron microscopy. Of note, tubuloreticular
or fingerprint like structures were not present. There-
fore, a very active diffuse global proliferative lupus neph-
ritis (WHO IV B, ISN/RPS IV-G (A)) was diagnosed. Of
note, no chronic changes, i.e. tubular atrophy or intersti-
tial fibrosis, were seen in the kidney. Due to mild de-
pressive mental state an additional EEG was performed.
The result showed dysrhythmic oscillations that led us
to hypothesize cerebral vasculitis. MRI angiography,
however, was normal.
After the diagnosis of severe proliferative lupus neph-
ritis was confrmed by renal biopsy we intensively
discussed the therapeutic options and decided to imme-
diately initiate the standard immunosuppressive treat-
ment schedule according to the Euro Lupus Trial [3]
with methylprednisolone pulse therapy (4 pulses with
400/200/200/100 mg/m² BSA respectively) followed byoral prednisone administration tapered from 60 to
10 mg/m²/48 h over an 48 week period, intravenous
cyclophosphamide pulse (in total 6 pulses in 4 weeks
interval) and additionally 10 courses of immunoadsorp-




Figure 2 Immunofluorescence of the kidney biopsy. Here, the typical “full-house” pattern with intense (+++) granular staining for IgA, IgG,
IgM (not shown), C1 and C3 in a diffuse mesangiocapillary pattern can be seen.
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intermittent hemodialysis due to oligoanuria and antihy-
pertensive treatment with amlodipine, atenolol and ena-
lapril. She received pneumocyctis carinii prophylaxis and
standard therapy for end stage renal disease. As no sub-
stantial improvement of renal function could be achieved
after the 2nd CPH pulse and immunoadsorption, the
patient received a Cimino fistula for intermittent
hemodialysis. Unexpectedly, in the further follow-up di-
uresis increased and subsequently also serum creatinine
levels substantially improved so that hemodialysis could
be discontinued about 12 weeks after initial admission.
Maintenance immunosuppressive therapy with mycophe-
nolate mofetil (MMF) was started 3 months after admis-
sion (Figure 3). Of course at this stage a re-biopsy would






Figure 3 Immunosuppressive treatment regime: The patient was initi
6 cyclophosphamide pulses (CPH) and immunoadsorption (10 course
3 months after admission. After 12 weeks permanent discontinuation of hethis was discussed with the patient and her parents who
refused in view of the positive clinical course and the
well-known, albeit low risk of a kidney biopsy.
At further follow-up creatinine levels, proteinuria and
complement C3 values improved and returned to nor-
mal range. ANA and dsDNA antibodies were only inter-
mittently detectable. The patient had 2 short episodes of
clinical relapse with leukopenia, proteinuria and increase
in dsDNA that were successfully treated for 4 weeks
with an increased dosage of oral steroids. Today, six
years after the initial presentation the patient is in
complete remission under permanent immunosuppres-
sion with MMF (2x750mg) in combination with prednis-
one (5 mg/48 h) and enalapril (40 mg). She has normal
renal function with creatinine levels continuously in the





ally treated with 4 methylprednisolone pulses (MPH),
s). Mycophenolate mofetil (MMF) was started as maintenance therapy
modialysis treatment was successful.
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The most striking observation in the presented case is
the unexpected complete recovery of renal function after
a long period of dependency on hemodialysis in a 12 year
old girl with severe proliferating lupus nephritis (WHO
class IV) and 80% glomeruli with cellular crescents.
In ANCA associated pauci-immune glomerulonephritis
it is known that a high number of crescents correlates
with the potential of recovery and that amelioration by
immunosuppressive therapy can be achieved [4]. In pro-
liferative lupus nephritis, however, a high activity index
with more than 50% of glomerular crescents is a risk fac-
tor associated with further progression of nephritis [5].
In our patient kidney function severely deteriorated and
oliguria persisted despite rapid improvement of general
condition after steroid and cyclophosphamide treatment
in combination with immunoadsorption. Due to the
known bad prognosis of proliferative lupus nephritis
[6,7] and in view of the young age of the patient, we
decided to apply an aggressive immunosuppressive treat-
ment to try to rescue the patient from end stage renal
failure. Although data on the efficacy of immunoadsorp-
tion and plasmapheresis in SLE are controversial, both
are rescue therapies in patients with various autoimmune
diseases. Immunoadsorption is associated with an accept-
able risk of bacterial and viral infection and it has been
recently shown that it leads to reduction in proteinuria,
anti-dsDNA antibodies and general disease activity in
SLE [8].
After the 2nd CPH pulse and 5 weeks after admission
the reasonability of further CPH pulses was debated as
the patients general condition was good. Serological
parameters were back to normal and improvement of
kidney function seemed unlikely. The worth and risk of
the treatment was discussed in view of the well-known
severe side effects of an aggressive immunosuppression
i.e. infections, hypertension, nonvascular bone necrosis,
osteoporosis but also lethal outcome are known [9]. A
decision was made for the continuation of the treatment
and fortunately no systemic infection, no bone affections
or comparable severe side effects occurred. Interestingly
and unexpected in view of the very grave histological
findings at presentation and the long dependency on
dialysis treatment, her renal function recovered so that
hemodialysis could be stopped after 12 weeks. Under
continuous MMF and low dose steroid therapy renal
function remained stable for now 6 years and the patient
is in a very good general condition with normal renal
function and without proteinuria. Only 2 short episodes
of clinical relapses of SLE occurred that were success-
fully treated with increased steroid dosage for a 4 week
period. Although complete remission of proliferative
glomerular lesions is very rare one could imagine that
the reparative capacity of the young and adolescentkidney in the absence of any chronic glomerular or
tubulointerstitial lesions is high enough for nearly
complete recovery from renal lesions. We have seen a
similar favourable course in a 16 year old patient with
acute renal failure due to severe crescentic anti-GBM
GN, who recovered after more than one year of
chronic hemodialysis treatment [10] and also Benseler
et al. [11] described some pediatric patients with lupus
nephritis in whom dialysis could be stopped after ad-
equate treatment.
The issue of renal recovery is certainly complex: it is
well known that severe lupus nephritis can result in a
need for dialysis in SLE patients, many of whom re-
cover despite being on prolonged dialysis. As shown
by Chu and Folkert [12] recovery of renal function in
chronic dialysis patients occurred mainly in cases with
autoimmune disease, especially lupus nephritis. The
rate of renal function recovery in this group of
patients approaches 10–28%, and occurs at a median
time of 3–18 months [13-17]. Hence the treatment of
severe class IV lupus nephritis should be continued for
up to 6 months in order to promote recovery as was
the case in our patient.
Conclusion
In the absence of chronic lesions of the kidney and
probably partly due to the high capacity of the kidney in
children and young adults to recover, complete remis-
sion of renal failure caused by severe proliferative lupus
nephritis even after several months of hemodialysis is
possible when an aggressive anti-inflammatory and im-
munosuppressive treatment regime according to stand-
ard protocols is used without delay. The favourable
course of the case presented here may encourage physi-
cians confronted with similar cases. In elderly patients
with comparable renal disease mostly chronic lesions are
already present so that a similar positive outcome can-
not necessarily be expected.
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